Lawrence Lehrner, MD
Nephrology · Las Vegas, NVNPI 1083604094
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,898 of the $8,487 with a category attached, or 69.5%. AstraZeneca accounts for 76.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $6,427 and has fallen 93.6% since, to $409 in 2025. Among nephrology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $122.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Amgen$508
- Biomerieux Inc$442
- Boehringer Ingelheim$263
- Novartis$212
- Calliditas Therapeutics US Inc.$124
- plus $474 from 12 others
Across 52 payments — averaging $4429.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$197K
- Baxter Healthcare$21K
- AstraZeneca$13K
- Janssen Research & Development, LLC$27
What the payments were for
- Consulting fees$5,89870%
- Travel & lodging$7068%
- Food & beverage$1,88222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $6,463 |
| Amgen(2 entities) | 13 | $508 |
| Biomerieux Inc | 1 | $442 |
| Boehringer Ingelheim | 6 | $263 |
| Novartis | 11 | $212 |
| Calliditas Therapeutics US Inc. | 1 | $124 |
| Aurinia Pharma U.S., Inc. | 4 | $98 |
| Merck | 2 | $69 |
| Vifor Pharma, Inc. | 3 | $52 |
| Ardelyx, Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $35 |
| GSK | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,487 in reported general payments places this provider in the 90th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 86 | $136,739 |
| FarxigaDapagliflozin Propanediol | 112 | $116,062 |
| JardianceEmpagliflozin | 58 | $70,067 |
| DapagliflozinDapagliflozin Propanediol | 12 | $11,111 |
| Potassium Citrate ErPotassium Citrate | 14 | $2,100 |
| Losartan Potassium | 138 | $1,565 |
| Paricalcitol | 23 | $1,276 |
| Lisinopril | 116 | $1,042 |
| Hydralazine Hcl | 20 | $607 |
| Febuxostat | 12 | $558 |
| Nifedipine ErNifedipine | 11 | $524 |
| Carvedilol | 23 | $300 |
| Amlodipine Besylate | 44 | $124 |
| Allopurinol | 29 | $121 |
| Calcitriol | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $6,463 | $116,062112 claims |
| Boehringer IngelheimJardiance | $263 | $70,06758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 nephrology providers in Nevada.
Other nephrology in Las Vegas
- Samuel KantorLas Vegas$319K
- Richard CottieroLas Vegas$220K
- Mark VishnepolskyLas Vegas$68K
- Baishali NairLas Vegas$12K
- Gene OngLas Vegas$11K
- Jeffrey RyuLas Vegas$9K
- Luana PillonLas Vegas$9K
- Hassan OsmanLas Vegas$8K
- Marwan TakieddineLas Vegas$8K
- Prateek SangheraLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.